Gaithersburg, Maryland-based Novavax, whose experimental COVID-19 vaccine is now in limited human trials, has acquired Praha Vaccines A.S., gaining its biologics manufacturing facility in Bohumil, Czech Republic, for $167 million. Novavax said the facility could provide an annual capacity of more than 1 billion doses of its NVX-CoV2372 vaccine beginning next year. Novavax’s vaccine candidate showed promising results in animal studies this spring. It is currently testing the vaccine with 130 humans in Australia and expects to report results in July. If promising, Phase 2 trials will be conducted in multiple countries, including the United States. “Manufacturing capacity is a critical component of our strategy to deliver a vaccine for the COVID-19 pandemic,” said Novavax chief executive Stanley Erck. “This acquisition provides the vital assets required to produce more than 1 billion doses per year.”
Read the full article: Novavax Buys Czech Manufacturer for COVID-19 Vaccine Production //
Source: https://wtop.com/business-finance/2020/05/gaithersburgs-novavax-buys-czech-vaccine-manufacturer-for-covid-19-production